Plaque Psoriasis, Psoriatic Arthritis Clinical Trial
Official title:
Psoriasis and Beyond: A Worldwide Survey on the Understanding of Psoriatic Disease Among Patients With Psoriasis and Psoriatic Arthritis
| NCT number | NCT04614831 |
| Other study ID # | CAIN457A2023 |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | November 12, 2020 |
| Est. completion date | June 3, 2021 |
| Verified date | July 2021 |
| Source | Novartis |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
The study is a Worldwide Survey on the Understanding of Psoriatic Disease among Patients with Psoriasis and Psoriatic Arthritis.
| Status | Completed |
| Enrollment | 4978 |
| Est. completion date | June 3, 2021 |
| Est. primary completion date | June 3, 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 100 Years |
| Eligibility | Inclusion Criteria: 1. Patients who self-report to have been diagnosed with Psoriasis or Psoriasis and Psoriatic Arthritis before or at the time of data collection 2. Patients 18 years of age or older at the time of data collection 3. Patients who did not participate in surveys regarding Psoriasis or Psoriatic Arthritis in the last 4 weeks 4. Body Surface Area (BSA) of >5 to <10, with psoriasis affecting sensitive and/or prominent body parts: face, palms, hands, fingers, genitals, soles of feet or nails or a BSA of 10 and above, when psoriasis was at its worst |
| Country | Name | City | State |
|---|---|---|---|
| Switzerland | Novartis Investigational Site | Basel |
| Lead Sponsor | Collaborator |
|---|---|
| Novartis Pharmaceuticals |
Switzerland,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | A web-based survey will be answered by the participants. Data collected for the analysis of the primary objective include validated patient-reported outcomes (such as DLQI), as well as responses to non-validated questions. | To assess patients' understanding of psoriasis and psoriatic arthritis as part of a systemic disease and the humanistic and physical burden of living with the condition. | 1 Day of survey | |
| Secondary | A web-based survey will be answered by the participants. The data collected for the analysis of the secondary objectives include validated tools (such as PAM-13), as well as responses to non-validated questions. | To assess the patient's perceptions and attitudes related to the relationship with their physician, the patient journey through the healthcare system, as well as barriers to self-management, diagnosis, patient perceptions on biologics, treatment expectations, and satisfaction with care. | 1 Day of Survey |